Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
Seung Bum Lee, Hee Seung Hong, Chang Kyun Lee, Bo-In Lee, Sol Kim, Seong-Joon Koh, Hosun Yu, Jung-Bin Park, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park,
Korean J Intern Med. 2023;38(5):661-671. Published online 2023 Jul 26 DOI: https://doi.org/10.3904/kjim.2022.394
Citations to this article as recorded by 
Management of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations
Yesim Ozguler, Sinem Nihal Esatoglu, Gunnar Tomasson, Louise Falzon, Stephane Barete, Alessandra Bettiol, Bahram Bodaghi, Vladimira Boyadzhieva, Luca Cantarini, Aykut Ferhat Celik, Omar Dhrif, Georgina Ducker, Giacomo Emmi, Ahmet Gül, Jörg Henes, Ina Koet
EULAR Rheumatology Open.2026; 2(2): 100152. CrossRef
Drug survival of adalimumab across different manifestations of Behçet’s syndrome: a retrospective analysis in 335 patients
Ozge Sonmez, Sinem Nihal Esatoglu, Didar Ucar, Elif Kaymaz, Yesim Ozguler, Serdal Ugurlu, Emire Seyahi, Melike Melikoglu, Izzet Fresko, Ugur Uygunoglu, Muazzez Cigdem Oba, Zekayi Kutlubay, Ali Ibrahim Hatemi, Aykut Ferhat Celik, Vedat Hamuryudan, Gulen Ha
Rheumatology.2026;[Epub] CrossRef
Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behçet’s disease
Sumei Sha, Bin Xu, Kairuo Wang, Chenyang Qiao, Haitao Shi, Jiong Jiang, Xiaojing Quan, Xin Liu
Frontiers in Immunology.2024;[Epub] CrossRef